The gene and cell therapy industry is in an exciting phase of growth, undergoing significant M&A activity, product sales and new marketing authorisations that are being issued with increasing regularity globally.
Our team works with a number of companies operating in this space to ensure they have robust patent applications. In relation to CAR-T and technology around the delivery of gene and cell therapies, such as vector platforms, we advise on both pre- and post-grant proceedings, including strategic filing advice, patent prosecution, as well as freedom to operate risk assessments.
We have also worked extensively in the cell therapy sector, providing prosecution and opposition advice to a number of companies with stem-cell based products.
As this field gets more crowded, a rise in contentious proceedings is inevitable. Our team has particular experience in representing parties in opposition and appeal proceedings at the EPO.
We also work closely with our regulatory expert colleagues who advise regularly in relation to orphan designation and data exclusivity strategies, which play a significant role in this field.
